Key Highlights

● ZBH closed at $89.05 on 9 October 2026.

● The second data set consensus target is $106.82, implying about 20 per cent upside.

● Targets range from $93 to $130.

● Following August results, Canaccord Genuity raised its target from $83 to $100.

Zimmer Biomet (NYSE:ZBH), a member of the S&P 500, closed at $89.05 on Friday 9 October 2026. Analyst targets sit well above that level, with the consensus implying upside of about 20 per cent, and ratings lean neutral.

What Is the Latest Analyst Price Target?

The second data set, using third-party data from 28 analysts, shows a mean target of $106.82, a median of $105, a high of $130 and a low of $93. Against the $89.05 close, the consensus target suggests upside of about 20 per cent.

Market data shows a lower average of $103.33 from 22 ratings in the past 12 months, with a range of $90 to $120, implying about 16 per cent upside.

What Are Wall Street Analysts Saying?

Sentiment is cautious rather than bullish. The second data set counts 19 Hold ratings among 28, with nine Buy-type ratings and no Sells, and summarises the consensus as Buy. Market data records six Buy, 15 Hold and one Sell, and calls the consensus Hold. The Hold majority is the common thread.

Recent actions on market data include Barclays upgrading to a Hold rating on 7 October 2026 and Citigroup and BMO Capital Markets reiterating Neutral and Market Perform ratings in late September and early October. Following August results, Canaccord Genuity raised its target from $83 to $100, Truist from $92 to $106, Royal Bank of Canada from $101 to $110 and Stifel from $105 to $110. UBS reiterated a Buy rating with a $120 target.

What Could Help the Stock Reach the Price Target?

If accurate, a consistent earnings beat and cost savings could support the higher targets.

Further upgrades from the large Hold camp, steady demand for joint-replacement procedures and evidence that restructuring is lifting margins are the sort of developments that could narrow the gap to the consensus target.

What Could Prevent the Stock Reaching the Target?

With 15 of 22 market data ratings at Hold, many analysts do not see a clear case for strong outperformance. The spread between the lowest target of $90 or $93 and the highest of $120 or $130 shows wide disagreement about fair value. Restructuring programmes carry execution risk, and medical device companies face pricing pressure, hospital budget constraints, regulatory requirements and competition in orthopaedics.

What Should Investors Watch Next?

Investors may want to follow the next quarterly results, any guidance update, and further broker moves after the early-October Barclays upgrade.

Zimmer Biomet Versus Its Analyst Targets

Zimmer Biomet closed at $89.05 on 9 October 2026, against a second data set consensus target of $106.82. Following August results, Canaccord Genuity raised its target from $83 to $100, Truist from $92 to $106, Royal Bank of Canada from $101 to $110 and Stifel from $105 to $110.